#Astrazenecaplc

U.S. drugmaker Bristol Myers Squibb inked a partnership with a Chinese company that some say could mark the next wave of collaboration across continents.

The advisory panel wasn't convinced that a clinical trial proved that early switching to camizestrant improved long-term survival rates.

AstraZeneca and GSK, the U.K.'s second and ninth most valuable companies, both saw first-quarter profits beat expectations early Wednesday.